Prognosis
U.S. Vaccine Patent Surprise Roils Pharma as WTO Debate Heats Up
- EU, China willing to join the discussion on U.S. proposal
- Tai Says discussions won’t be easy amid pharma opposition
This article is for subscribers only.
The U.S.’s sudden support for a waiver of patent protections for Covid-19 vaccines is headed for potentially thorny negotiations at the World Trade Organization over sharing the proprietary know-how needed to boost global supplies.
“In terms of how soon the WTO can deliver -- that literally depends on the WTO members, collectively, being able to deliver,” U.S. Trade Representative Katherine Tai said in an interview Wednesday. “I am the first one to admit that what we are leaning into is a process that is not going to be easy.”